Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Share-based Compensation (2020 - 2025)

Arcutis Biotherapeutics has reported Share-based Compensation over the past 6 years, most recently at $10.1 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $10.1 million for Q4 2025, up 7.1% from a year ago — trailing twelve months through Dec 2025 was $40.4 million (down 3.27% YoY), and the annual figure for FY2025 was $40.4 million, down 3.27%.
  • Share-based Compensation for Q4 2025 was $10.1 million at Arcutis Biotherapeutics, roughly flat from $10.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for ARQT hit a ceiling of $12.5 million in Q2 2024 and a floor of $4.3 million in Q2 2021.
  • Median Share-based Compensation over the past 5 years was $9.4 million (2023), compared with a mean of $8.9 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 758.89% in 2021 and later dropped 23.17% in 2022.
  • Arcutis Biotherapeutics' Share-based Compensation stood at $5.7 million in 2021, then skyrocketed by 62.93% to $9.3 million in 2022, then decreased by 5.47% to $8.8 million in 2023, then increased by 7.26% to $9.4 million in 2024, then grew by 7.1% to $10.1 million in 2025.
  • The last three reported values for Share-based Compensation were $10.1 million (Q4 2025), $10.0 million (Q3 2025), and $10.5 million (Q2 2025) per Business Quant data.